Optimizing management of upper tract urothelial carcinoma
Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these t...
Saved in:
| Published in | Urologic oncology Vol. 35; no. 7; pp. 492 - 498 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.07.2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1078-1439 1873-2496 1873-2496 |
| DOI | 10.1016/j.urolonc.2017.05.009 |
Cover
| Abstract | Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease. Patients with UTUC have high rates of microsatellite instability and fibroblast growth factor receptor 3 mutations as compared to their bladder counterparts presenting unique, important subsets in UTUC. Immune checkpoint inhibitors targeting the programmed death receptor 1 and ligand have provided a new second-line treatment option for patients with UTUC and appear particularly well suited for patients with microsatellite instability. More work in understanding the molecular gene signatures and its relationship to response to chemotherapy, immunotherapy, and targeted therapy is needed to continually optimize care for patients with all stages of disease. Advances in UTUC are possible, when one accounts for the unique clinical and biological features of this disease. |
|---|---|
| AbstractList | Abstract Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease. Patients with UTUC have high rates of microsatellite instability and fibroblast growth factor receptor 3 mutations as compared to their bladder counterparts presenting unique, important subsets in UTUC. Immune checkpoint inhibitors targeting the programmed death receptor 1 and ligand have provided a new second-line treatment option for patients with UTUC and appear particularly well suited for patients with microsatellite instability. More work in understanding the molecular gene signatures and its relationship to response to chemotherapy, immunotherapy, and targeted therapy is needed to continually optimize care for patients with all stages of disease. Advances in UTUC are possible, when one accounts for the unique clinical and biological features of this disease. Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease. Patients with UTUC have high rates of microsatellite instability and fibroblast growth factor receptor 3 mutations as compared to their bladder counterparts presenting unique, important subsets in UTUC. Immune checkpoint inhibitors targeting the programmed death receptor 1 and ligand have provided a new second-line treatment option for patients with UTUC and appear particularly well suited for patients with microsatellite instability. More work in understanding the molecular gene signatures and its relationship to response to chemotherapy, immunotherapy, and targeted therapy is needed to continually optimize care for patients with all stages of disease. Advances in UTUC are possible, when one accounts for the unique clinical and biological features of this disease. Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease. Patients with UTUC have high rates of microsatellite instability and fibroblast growth factor receptor 3 mutations as compared to their bladder counterparts presenting unique, important subsets in UTUC. Immune checkpoint inhibitors targeting the programmed death receptor 1 and ligand have provided a new second-line treatment option for patients with UTUC and appear particularly well suited for patients with microsatellite instability. More work in understanding the molecular gene signatures and its relationship to response to chemotherapy, immunotherapy, and targeted therapy is needed to continually optimize care for patients with all stages of disease. Advances in UTUC are possible, when one accounts for the unique clinical and biological features of this disease.Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease. Patients with UTUC have high rates of microsatellite instability and fibroblast growth factor receptor 3 mutations as compared to their bladder counterparts presenting unique, important subsets in UTUC. Immune checkpoint inhibitors targeting the programmed death receptor 1 and ligand have provided a new second-line treatment option for patients with UTUC and appear particularly well suited for patients with microsatellite instability. More work in understanding the molecular gene signatures and its relationship to response to chemotherapy, immunotherapy, and targeted therapy is needed to continually optimize care for patients with all stages of disease. Advances in UTUC are possible, when one accounts for the unique clinical and biological features of this disease. |
| Author | Campbell, Matthew T. Matin, Surena F. Siefker-Radtke, Arlene O. Shah, Amishi Y. |
| Author_xml | – sequence: 1 givenname: Matthew T. surname: Campbell fullname: Campbell, Matthew T. email: mcampbell3@mdanderson.org organization: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 2 givenname: Amishi Y. surname: Shah fullname: Shah, Amishi Y. organization: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 3 givenname: Surena F. surname: Matin fullname: Matin, Surena F. organization: Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 4 givenname: Arlene O. surname: Siefker-Radtke fullname: Siefker-Radtke, Arlene O. organization: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28579283$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtv1TAQhS1URB_wE0BZskkYJ07sCAFCFY9KlbpoWVvOZFJ8SexgO0jl15PoXlhUqsrKszjnjOc7p-zIeUeMveRQcODNm12xBD96h0UJXBZQFwDtE3bClazyUrTN0TqDVDkXVXvMTmPcAXChOH_GjktVy7ZU1Qlrr-ZkJ_vbuttsMs7c0kQuZX7IlnmmkKVgMGXrqvSdRmvGDE1A6_xknrOngxkjvTi8Z-zb508351_zy6svF-cfL3MUUqS86ruWKy4EcdNRZzrs-qppkIzoepACkFCWEoayrru6boZKDao1WA4KFci6OmOv97lz8D8XiklPNiKNo3Hkl6h5Cw0XDahmlb46SJduol7PwU4m3Om_566Cei_A4GMMNPyTcNAbVr3TB6x6w6qh1ivW1ff2ng9tMsl6t_Kx46PuD3s3rZh-WQo6oiWH1NtAmHTv7aMJ7-8l4GidRTP-oDuKO78Et3aguY6lBn29Fb_1zmUFJW-3w989HPAfH_gDYAnBNg |
| CitedBy_id | crossref_primary_10_36290_uro_2019_081 crossref_primary_10_1016_j_jasc_2020_06_011 crossref_primary_10_1016_j_urolonc_2018_12_002 crossref_primary_10_1007_s11864_019_0637_2 crossref_primary_10_1016_j_bulcan_2018_07_017 crossref_primary_10_1016_j_ejrad_2017_10_021 crossref_primary_10_1016_j_euf_2020_08_001 crossref_primary_10_1093_ajcp_aqaa105 crossref_primary_10_3389_fruro_2022_903693 crossref_primary_10_1097_PAI_0000000000000957 crossref_primary_10_1016_j_urolonc_2017_05_023 crossref_primary_10_37349_etat_2024_00274 crossref_primary_10_3390_cancers14194841 |
| Cites_doi | 10.1016/S0090-4295(97)00230-6 10.1016/j.ejcsup.2016.01.001 10.1111/j.1464-410X.2009.08838.x 10.1200/JCO.2006.08.0994 10.1002/cncr.24135 10.1016/j.ejso.2014.06.007 10.1016/S1470-2045(16)30496-X 10.1097/01.MP.0000024263.25043.0C 10.1016/j.eururo.2016.07.014 10.1111/j.1464-410X.2012.11649.x 10.1016/j.eururo.2015.06.044 10.1016/j.urology.2015.12.007 10.1038/nature12965 10.1016/j.ccr.2014.01.009 10.1016/S0022-5347(05)67019-X 10.1016/j.juro.2017.02.2257 10.1016/j.urology.2004.04.024 10.1016/j.urolonc.2011.07.011 10.1016/j.eururo.2006.12.029 10.1038/nature13904 10.1016/j.eururo.2015.07.039 10.1002/cncr.25050 10.1016/j.eururo.2013.08.033 10.1016/j.ebiom.2016.08.036 10.1038/ki.2011.371 10.1056/NEJMoa022148 10.1016/j.eururo.2015.08.034 10.1111/j.1464-410X.2011.10288.x 10.1158/1078-0432.CCR-12-0077-T 10.3322/caac.21332 10.1200/JCO.2015.64.1076 10.1002/cncr.28655 10.1371/journal.pone.0137141 10.1093/annonc/mdw373.14 10.1200/JCO.2012.45.2128 10.1016/j.eururo.2011.05.064 10.1093/annonc/mdw373.09 10.1002/cncr.20123 10.1136/jmg.2010.076992 10.1002/cncr.22031 10.1016/j.urolonc.2014.02.018 10.1056/NEJMoa1500596 10.1073/pnas.1318376111 10.1016/j.eururo.2014.03.003 10.1016/j.urolonc.2009.03.021 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Inc. Elsevier Inc. Copyright © 2017 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2017 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2017 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.urolonc.2017.05.009 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-2496 |
| EndPage | 498 |
| ExternalDocumentID | 28579283 10_1016_j_urolonc_2017_05_009 S1078143917302193 1_s2_0_S1078143917302193 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: National Cancer Institute grantid: P50 CA091846) – fundername: National Cancer Center grantid: CA016672 |
| GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 123 1B1 1P~ 1~. 1~5 29Q 4.4 457 4CK 4G. 53G 5RE 5VS 6PF 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ADBBV ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AEVXI AFJKZ AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SEL SES SEW SSH SSZ T5K UDS UHS Z5R ZGI ~G- AACTN AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD |
| ID | FETCH-LOGICAL-c474t-3db918144e1abebabcbd366cea4bd0740cec7270f255b556f38f89ac2f8c80753 |
| IEDL.DBID | .~1 |
| ISSN | 1078-1439 1873-2496 |
| IngestDate | Sat Sep 27 20:30:00 EDT 2025 Wed Feb 19 02:42:12 EST 2025 Thu Apr 24 22:57:33 EDT 2025 Tue Jul 01 00:59:27 EDT 2025 Fri Feb 23 02:13:26 EST 2024 Tue Feb 25 20:09:44 EST 2025 Tue Aug 26 16:32:13 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Urothelial cancer Chemotherapy Renal pelvis Upper tract |
| Language | English |
| License | Copyright © 2017 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-3db918144e1abebabcbd366cea4bd0740cec7270f255b556f38f89ac2f8c80753 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 28579283 |
| PQID | 1906146086 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1906146086 pubmed_primary_28579283 crossref_primary_10_1016_j_urolonc_2017_05_009 crossref_citationtrail_10_1016_j_urolonc_2017_05_009 elsevier_sciencedirect_doi_10_1016_j_urolonc_2017_05_009 elsevier_clinicalkeyesjournals_1_s2_0_S1078143917302193 elsevier_clinicalkey_doi_10_1016_j_urolonc_2017_05_009 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-07-01 |
| PublicationDateYYYYMMDD | 2017-07-01 |
| PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Urologic oncology |
| PublicationTitleAlternate | Urol Oncol |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Dreicer, Manola, Roth, See, Kuross, Edelman (bib31) 2004; 100 Le, Uram, Wang, Bartlett, Kemberling, Eyring (bib39) 2015; 372 Leow, Martin-Doyle, Rajagopal, Patel, Anderson, Rothman (bib24) 2014; 66 Hussain, MacVicar, Petrylak, Dunn, Vaishampayan, Lara (bib33) 2007; 25 Yakoubi, Colin, Seisen, Léon, Nison, Bozzini (bib17) 2014; 40 bib37 Sharma, Callahan, Bono, Kim, Spiliopoulou, Calvo (bib36) 2016; 17 Damrauer, Hoadley, Chism, Fan, Tiganelli, Wobker (bib41) 2014; 111 McConkey, Choi, Shen, Lee, Porten, Matin (bib44) 2016; 69 Colin, Koenig, Ouzzane, Berthon, Villers, Biserte (bib7) 2009; 104 Moss, Yi, Peng, Xi, Mosqueda, Guo (bib47) 2017; 197 Choi, Porten, Kim, Willis, Plimack, Hoffman-Censits (bib40) 2015; 25 Munoz, Ellison (bib6) 2000; 164 Siegel, Miller, Ahmed (bib4) 2016; 66 Leow, Martin-Doyle, Fay, Choueiri, Chang, Bellmunt (bib26) 2014; 66 Sanford, Porten, Meng (bib46) 2015; 10 Sfakianos, Cha, Iyer, Scott, Zabor, Shah (bib48) 2015; 68 Margulis, Shariat, Matin, Kamat, Zigeuner, Kikuchi (bib15) 2009; 115 O’Brien, Ray, Singh, Coker, Beard (bib21) 2011; 60 Siefker-Radtke, Campbell, Munsell, Harris, Carolla, Pagliaro (bib34) 2016; 89 Kilgore, Angell, Smith, Ahdesmake, Barrett, Harrington, Hurst (bib49) 2016 van der Post, Kiemeney, Ligtenberg, Witjes, Hulsbergen-van de Kaa, Bodmer (bib38) 2010; 47 Jelakovic, Karanovic, Vukovic-Lela, Miller, Edwards, Nikolić (bib8) 2012; 81 Tawfiek, Bagley (bib5) 1997; 50 Ito, Shintaku, Satoh, Ioritani, Aizawa, Tochigi (bib20) 2013; 31 Matin, Margulis, Kamat, Wood, Grossman, Brown (bib1) 2010; 116 Linardou, Aravantinos, Efstathiou, Kalofonos, Anagnostopoulos, Deliveliotis (bib32) 2004; 64 Dogliotti, Cartenì, Siena, Bertetto, Martoni, Bono, Amadori (bib30) 2007; 52 Seisen, Peyronnet, Dominguez-Escrig, Bruins, Yuan, Babjuk (bib19) 2016; 70 Dadhania, Zhang, Zhang, Bondaruk, Majewski, Siefker-Radtke (bib45) 2016; 12 McConkey, Choi, Shen, Lee, Porten, Matin (bib2) 2016; 69 Porten, Siefker-Radtke, Xiao, Margulis, Kamat, Wood (bib25) 2014; 120 Messer, Terrell, Herman, Ng, Scherr, Scoll (bib13) 2013; 31 Rouprêt, Babjuk, Compérat, Zigeuner, Sylvester, Burger (bib18) 2015; 68 Grossman, Natale, Tangen, Speights, Vogelzang, Trump (bib22) 2003; 349 Favaretto, Shariat, Savage, Godoy, Chade, Kaag (bib12) 2012; 109 Porter, Kerrigan, Donato, Ramsey (bib27) 2011; 29 Sjödahl, Lauss, Lövgren, Chebil, Gudjonsson, Veerla (bib43) 2012; 18 Soria, Italiano, Cervantes, Tabernero, Infante, Lara (bib50) 2016 Dash, Galsky, Vickers, Serio, Koppie, Dalbagni (bib29) 2006; 107 Galsky, Stensland, Moshier, Sfakianos, McBride, Tsao (bib23) 2016; 34 Bellmunt, Mottet, De Santis (bib28) 2016; 14 Xylinas, Rink, Margulis, Clozel, Lee, Comploj (bib11) 2013; 112 Hartmann, Zanardo, Bocker-Edmonston, Blaszyk, Dietmaier, Stoehr (bib10) 2002; 62 Powles, Eder, Fine, Braiteh, Loriot, Cruz (bib35) 2014; 515 bib16 (bib42) 2014; 507 Blaszyk, Wang, Dietmaier, Hofstädter, Burgart, Cheville (bib9) 2002; 15 Siefker-Radtke, Campbell (bib3) 2017; 35 Chung, Krabbe, Darwish, Westerman, Bagrodia, Gayed (bib14) 2014; 32 Messer (10.1016/j.urolonc.2017.05.009_bib13) 2013; 31 Sanford (10.1016/j.urolonc.2017.05.009_bib46) 2015; 10 Chung (10.1016/j.urolonc.2017.05.009_bib14) 2014; 32 Hussain (10.1016/j.urolonc.2017.05.009_bib33) 2007; 25 Moss (10.1016/j.urolonc.2017.05.009_bib47) 2017; 197 Dogliotti (10.1016/j.urolonc.2017.05.009_bib30) 2007; 52 Hartmann (10.1016/j.urolonc.2017.05.009_bib10) 2002; 62 Seisen (10.1016/j.urolonc.2017.05.009_bib19) 2016; 70 Grossman (10.1016/j.urolonc.2017.05.009_bib22) 2003; 349 Porter (10.1016/j.urolonc.2017.05.009_bib27) 2011; 29 McConkey (10.1016/j.urolonc.2017.05.009_bib44) 2016; 69 Rouprêt (10.1016/j.urolonc.2017.05.009_bib18) 2015; 68 Blaszyk (10.1016/j.urolonc.2017.05.009_bib9) 2002; 15 Bellmunt (10.1016/j.urolonc.2017.05.009_bib28) 2016; 14 Siegel (10.1016/j.urolonc.2017.05.009_bib4) 2016; 66 Dreicer (10.1016/j.urolonc.2017.05.009_bib31) 2004; 100 Margulis (10.1016/j.urolonc.2017.05.009_bib15) 2009; 115 Xylinas (10.1016/j.urolonc.2017.05.009_bib11) 2013; 112 Kilgore (10.1016/j.urolonc.2017.05.009_bib49) 2016 Matin (10.1016/j.urolonc.2017.05.009_bib1) 2010; 116 Yakoubi (10.1016/j.urolonc.2017.05.009_bib17) 2014; 40 Powles (10.1016/j.urolonc.2017.05.009_bib35) 2014; 515 Tawfiek (10.1016/j.urolonc.2017.05.009_bib5) 1997; 50 Le (10.1016/j.urolonc.2017.05.009_bib39) 2015; 372 Munoz (10.1016/j.urolonc.2017.05.009_bib6) 2000; 164 Colin (10.1016/j.urolonc.2017.05.009_bib7) 2009; 104 Linardou (10.1016/j.urolonc.2017.05.009_bib32) 2004; 64 Choi (10.1016/j.urolonc.2017.05.009_bib40) 2015; 25 Dadhania (10.1016/j.urolonc.2017.05.009_bib45) 2016; 12 Soria (10.1016/j.urolonc.2017.05.009_bib50) 2016 Leow (10.1016/j.urolonc.2017.05.009_bib26) 2014; 66 Damrauer (10.1016/j.urolonc.2017.05.009_bib41) 2014; 111 McConkey (10.1016/j.urolonc.2017.05.009_bib2) 2016; 69 (10.1016/j.urolonc.2017.05.009_bib42) 2014; 507 Galsky (10.1016/j.urolonc.2017.05.009_bib23) 2016; 34 Favaretto (10.1016/j.urolonc.2017.05.009_bib12) 2012; 109 Leow (10.1016/j.urolonc.2017.05.009_bib24) 2014; 66 Jelakovic (10.1016/j.urolonc.2017.05.009_bib8) 2012; 81 Sfakianos (10.1016/j.urolonc.2017.05.009_bib48) 2015; 68 van der Post (10.1016/j.urolonc.2017.05.009_bib38) 2010; 47 Sharma (10.1016/j.urolonc.2017.05.009_bib36) 2016; 17 Porten (10.1016/j.urolonc.2017.05.009_bib25) 2014; 120 Siefker-Radtke (10.1016/j.urolonc.2017.05.009_bib3) 2017; 35 Ito (10.1016/j.urolonc.2017.05.009_bib20) 2013; 31 Siefker-Radtke (10.1016/j.urolonc.2017.05.009_bib34) 2016; 89 Sjödahl (10.1016/j.urolonc.2017.05.009_bib43) 2012; 18 O’Brien (10.1016/j.urolonc.2017.05.009_bib21) 2011; 60 Dash (10.1016/j.urolonc.2017.05.009_bib29) 2006; 107 |
| References_xml | – volume: 66 start-page: 529 year: 2014 end-page: 541 ident: bib26 article-title: A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma publication-title: Eur Urol – volume: 10 start-page: e0137141 year: 2015 ident: bib46 article-title: Molecular analysis of upper tract and bladder urothelial carcinoma: results from a microarray comparison publication-title: PLoS One – volume: 31 start-page: 904 year: 2013 end-page: 908 ident: bib13 article-title: Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma publication-title: Urol Oncol – volume: 40 start-page: 1629 year: 2014 end-page: 1634 ident: bib17 article-title: Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies publication-title: Eur J Surg Oncol – volume: 32 start-page: 981 year: 2014 end-page: 988 ident: bib14 article-title: Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract publication-title: Urol Oncol – volume: 47 start-page: 464 year: 2010 end-page: 470 ident: bib38 article-title: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers publication-title: J Med Genet – volume: 60 start-page: 703 year: 2011 end-page: 710 ident: bib21 article-title: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial) publication-title: Eur Urol – volume: 62 start-page: 6796 year: 2002 end-page: 6802 ident: bib10 article-title: Frequent microsatellite instability in sporadic tumors of the upper urinary tract publication-title: Cancer Res – volume: 116 start-page: 3127 year: 2010 end-page: 3134 ident: bib1 article-title: Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma publication-title: Cancer – volume: 66 start-page: 7 year: 2016 end-page: 30 ident: bib4 article-title: Cancer Statistics, 2016 publication-title: CA Cancer J Clin – volume: 34 start-page: 825 year: 2016 end-page: 832 ident: bib23 article-title: Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer publication-title: J Clin Oncol – volume: 107 start-page: 506 year: 2006 end-page: 513 ident: bib29 article-title: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder publication-title: Cancer – volume: 29 start-page: 252 year: 2011 end-page: 258 ident: bib27 article-title: Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer publication-title: Urol Oncol – volume: 372 start-page: 2509 year: 2015 end-page: 2520 ident: bib39 article-title: PD-1 blockade in tumors with mismatch-repair deficiency publication-title: N Engl J Med – volume: 115 start-page: 1224 year: 2009 end-page: 1233 ident: bib15 article-title: Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration publication-title: Cancer – volume: 89 start-page: 83 year: 2016 end-page: 89 ident: bib34 article-title: Front-line treatment with gemcitabine, paclitaxel, and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study publication-title: Urology – volume: 66 start-page: 42 year: 2014 end-page: 54 ident: bib24 article-title: Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials publication-title: Eur Urol – volume: 52 start-page: 134 year: 2007 end-page: 141 ident: bib30 article-title: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial publication-title: Eur Urol – volume: 50 start-page: 321 year: 1997 end-page: 329 ident: bib5 article-title: Upper-tract transitional cell carcinoma publication-title: Urology – volume: 64 start-page: 479 year: 2004 end-page: 484 ident: bib32 article-title: Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group publication-title: Urology – volume: 31 start-page: 1422 year: 2013 end-page: 1427 ident: bib20 article-title: Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial publication-title: J Clin Oncol – volume: 515 start-page: 558 year: 2014 end-page: 562 ident: bib35 article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer publication-title: Nature – volume: 69 start-page: 855 year: 2016 end-page: 862 ident: bib44 article-title: A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer publication-title: Eur Urol – volume: 111 start-page: 3110 year: 2014 end-page: 3115 ident: bib41 article-title: Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology publication-title: Proc Natl Acad Sci U S A – volume: 164 start-page: 1523 year: 2000 end-page: 1525 ident: bib6 article-title: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades publication-title: J Urol – volume: 112 start-page: 453 year: 2013 end-page: 461 ident: bib11 article-title: Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy publication-title: BJU Int – volume: 197 start-page: e944 year: 2017 ident: bib47 article-title: Comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC) publication-title: J Urol – volume: 69 start-page: 855 year: 2016 end-page: 862 ident: bib2 article-title: A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer publication-title: Eur Urol – volume: 109 start-page: 77 year: 2012 end-page: 82 ident: bib12 article-title: Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma publication-title: BJU Int – year: 2016 ident: bib50 article-title: Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma publication-title: Ann Oncol – volume: 17 start-page: 1590 year: 2016 end-page: 1598 ident: bib36 article-title: Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial publication-title: Lancet Oncol – volume: 12 start-page: 105 year: 2016 end-page: 117 ident: bib45 article-title: Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use publication-title: EBioMedicine – volume: 104 start-page: 1436 year: 2009 end-page: 1440 ident: bib7 article-title: Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract publication-title: BJU Int – ident: bib16 – volume: 15 start-page: 790 year: 2002 end-page: 797 ident: bib9 article-title: Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis publication-title: Mod Pathol – volume: 25 start-page: 152 year: 2015 end-page: 165 ident: bib40 article-title: Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with differerent sensitivities to frontline chemotherapy publication-title: Cancer Cell – year: 2016 ident: bib49 article-title: Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates publication-title: Ann Oncol – ident: bib37 – volume: 68 start-page: 970 year: 2015 end-page: 977 ident: bib48 article-title: Genomic characterization of upper tract urothelial carcinoma publication-title: Eur Urol – volume: 35 start-page: 816 year: 2017 end-page: 817 ident: bib3 article-title: Now is the time for perioperative chemotherapy in upper tract urothelial cancer publication-title: J Clin Oncol – volume: 349 start-page: 859 year: 2003 end-page: 866 ident: bib22 article-title: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer publication-title: N Engl J Med – volume: 14 start-page: 1 year: 2016 end-page: 20 ident: bib28 article-title: Urothelial carcinoma management in elderly or unfit patients publication-title: EJC Suppl – volume: 18 start-page: 3377 year: 2012 end-page: 3386 ident: bib43 article-title: A molecular taxonomy for urothelial carcinoma publication-title: Clin Cancer Res – volume: 81 start-page: 559 year: 2012 end-page: 567 ident: bib8 article-title: Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid publication-title: Kidney Int – volume: 120 start-page: 1794 year: 2014 end-page: 1799 ident: bib25 article-title: Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma publication-title: Cancer – volume: 70 start-page: 1052 year: 2016 end-page: 1068 ident: bib19 article-title: Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel publication-title: Eur Urol – volume: 100 start-page: 1639 year: 2004 end-page: 1645 ident: bib31 article-title: Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium publication-title: Cancer – volume: 25 start-page: 2218 year: 2007 end-page: 2224 ident: bib33 article-title: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial publication-title: J Clin Oncol – volume: 68 start-page: 868 year: 2015 end-page: 879 ident: bib18 article-title: European guidelines on upper tract urothelial carcinomas: 2015 update publication-title: Eur Urol – volume: 507 start-page: 315 year: 2014 end-page: 322 ident: bib42 article-title: Comprehensive molecular characterization of urothelial bladder carcinoma publication-title: Nature – volume: 50 start-page: 321 year: 1997 ident: 10.1016/j.urolonc.2017.05.009_bib5 article-title: Upper-tract transitional cell carcinoma publication-title: Urology doi: 10.1016/S0090-4295(97)00230-6 – volume: 14 start-page: 1 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib28 article-title: Urothelial carcinoma management in elderly or unfit patients publication-title: EJC Suppl doi: 10.1016/j.ejcsup.2016.01.001 – volume: 104 start-page: 1436 year: 2009 ident: 10.1016/j.urolonc.2017.05.009_bib7 article-title: Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract publication-title: BJU Int doi: 10.1111/j.1464-410X.2009.08838.x – volume: 25 start-page: 2218 year: 2007 ident: 10.1016/j.urolonc.2017.05.009_bib33 article-title: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial publication-title: J Clin Oncol doi: 10.1200/JCO.2006.08.0994 – volume: 115 start-page: 1224 year: 2009 ident: 10.1016/j.urolonc.2017.05.009_bib15 article-title: Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration publication-title: Cancer doi: 10.1002/cncr.24135 – volume: 40 start-page: 1629 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib17 article-title: Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2014.06.007 – volume: 17 start-page: 1590 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib36 article-title: Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30496-X – volume: 15 start-page: 790 year: 2002 ident: 10.1016/j.urolonc.2017.05.009_bib9 article-title: Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis publication-title: Mod Pathol doi: 10.1097/01.MP.0000024263.25043.0C – volume: 70 start-page: 1052 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib19 article-title: Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel publication-title: Eur Urol doi: 10.1016/j.eururo.2016.07.014 – volume: 112 start-page: 453 year: 2013 ident: 10.1016/j.urolonc.2017.05.009_bib11 article-title: Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy publication-title: BJU Int doi: 10.1111/j.1464-410X.2012.11649.x – volume: 68 start-page: 868 year: 2015 ident: 10.1016/j.urolonc.2017.05.009_bib18 article-title: European guidelines on upper tract urothelial carcinomas: 2015 update publication-title: Eur Urol doi: 10.1016/j.eururo.2015.06.044 – volume: 89 start-page: 83 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib34 article-title: Front-line treatment with gemcitabine, paclitaxel, and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study publication-title: Urology doi: 10.1016/j.urology.2015.12.007 – volume: 507 start-page: 315 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib42 article-title: Comprehensive molecular characterization of urothelial bladder carcinoma publication-title: Nature doi: 10.1038/nature12965 – volume: 62 start-page: 6796 year: 2002 ident: 10.1016/j.urolonc.2017.05.009_bib10 article-title: Frequent microsatellite instability in sporadic tumors of the upper urinary tract publication-title: Cancer Res – volume: 25 start-page: 152 year: 2015 ident: 10.1016/j.urolonc.2017.05.009_bib40 article-title: Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with differerent sensitivities to frontline chemotherapy publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.01.009 – volume: 164 start-page: 1523 year: 2000 ident: 10.1016/j.urolonc.2017.05.009_bib6 article-title: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades publication-title: J Urol doi: 10.1016/S0022-5347(05)67019-X – volume: 197 start-page: e944 year: 2017 ident: 10.1016/j.urolonc.2017.05.009_bib47 article-title: Comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC) publication-title: J Urol doi: 10.1016/j.juro.2017.02.2257 – volume: 64 start-page: 479 year: 2004 ident: 10.1016/j.urolonc.2017.05.009_bib32 article-title: Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group publication-title: Urology doi: 10.1016/j.urology.2004.04.024 – volume: 31 start-page: 904 year: 2013 ident: 10.1016/j.urolonc.2017.05.009_bib13 article-title: Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma publication-title: Urol Oncol doi: 10.1016/j.urolonc.2011.07.011 – volume: 52 start-page: 134 year: 2007 ident: 10.1016/j.urolonc.2017.05.009_bib30 article-title: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial publication-title: Eur Urol doi: 10.1016/j.eururo.2006.12.029 – volume: 515 start-page: 558 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib35 article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer publication-title: Nature doi: 10.1038/nature13904 – volume: 68 start-page: 970 year: 2015 ident: 10.1016/j.urolonc.2017.05.009_bib48 article-title: Genomic characterization of upper tract urothelial carcinoma publication-title: Eur Urol doi: 10.1016/j.eururo.2015.07.039 – volume: 116 start-page: 3127 year: 2010 ident: 10.1016/j.urolonc.2017.05.009_bib1 article-title: Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma publication-title: Cancer doi: 10.1002/cncr.25050 – volume: 66 start-page: 42 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib24 article-title: Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials publication-title: Eur Urol doi: 10.1016/j.eururo.2013.08.033 – volume: 12 start-page: 105 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib45 article-title: Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use publication-title: EBioMedicine doi: 10.1016/j.ebiom.2016.08.036 – volume: 81 start-page: 559 year: 2012 ident: 10.1016/j.urolonc.2017.05.009_bib8 article-title: Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid publication-title: Kidney Int doi: 10.1038/ki.2011.371 – volume: 349 start-page: 859 year: 2003 ident: 10.1016/j.urolonc.2017.05.009_bib22 article-title: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa022148 – volume: 69 start-page: 855 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib2 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.08.034 – volume: 109 start-page: 77 year: 2012 ident: 10.1016/j.urolonc.2017.05.009_bib12 article-title: Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma publication-title: BJU Int doi: 10.1111/j.1464-410X.2011.10288.x – volume: 18 start-page: 3377 year: 2012 ident: 10.1016/j.urolonc.2017.05.009_bib43 article-title: A molecular taxonomy for urothelial carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-0077-T – volume: 66 start-page: 7 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib4 article-title: Cancer Statistics, 2016 publication-title: CA Cancer J Clin doi: 10.3322/caac.21332 – volume: 34 start-page: 825 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib23 article-title: Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2015.64.1076 – volume: 120 start-page: 1794 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib25 article-title: Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma publication-title: Cancer doi: 10.1002/cncr.28655 – volume: 10 start-page: e0137141 year: 2015 ident: 10.1016/j.urolonc.2017.05.009_bib46 article-title: Molecular analysis of upper tract and bladder urothelial carcinoma: results from a microarray comparison publication-title: PLoS One doi: 10.1371/journal.pone.0137141 – year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib49 article-title: Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates publication-title: Ann Oncol doi: 10.1093/annonc/mdw373.14 – volume: 31 start-page: 1422 year: 2013 ident: 10.1016/j.urolonc.2017.05.009_bib20 article-title: Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.2128 – volume: 60 start-page: 703 year: 2011 ident: 10.1016/j.urolonc.2017.05.009_bib21 article-title: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial) publication-title: Eur Urol doi: 10.1016/j.eururo.2011.05.064 – year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib50 article-title: Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma publication-title: Ann Oncol doi: 10.1093/annonc/mdw373.09 – volume: 69 start-page: 855 year: 2016 ident: 10.1016/j.urolonc.2017.05.009_bib44 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.08.034 – volume: 100 start-page: 1639 year: 2004 ident: 10.1016/j.urolonc.2017.05.009_bib31 article-title: Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium publication-title: Cancer doi: 10.1002/cncr.20123 – volume: 47 start-page: 464 year: 2010 ident: 10.1016/j.urolonc.2017.05.009_bib38 article-title: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers publication-title: J Med Genet doi: 10.1136/jmg.2010.076992 – volume: 107 start-page: 506 year: 2006 ident: 10.1016/j.urolonc.2017.05.009_bib29 article-title: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder publication-title: Cancer doi: 10.1002/cncr.22031 – volume: 32 start-page: 981 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib14 article-title: Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract publication-title: Urol Oncol doi: 10.1016/j.urolonc.2014.02.018 – volume: 372 start-page: 2509 year: 2015 ident: 10.1016/j.urolonc.2017.05.009_bib39 article-title: PD-1 blockade in tumors with mismatch-repair deficiency publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596 – volume: 111 start-page: 3110 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib41 article-title: Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1318376111 – volume: 66 start-page: 529 year: 2014 ident: 10.1016/j.urolonc.2017.05.009_bib26 article-title: A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma publication-title: Eur Urol doi: 10.1016/j.eururo.2014.03.003 – volume: 29 start-page: 252 year: 2011 ident: 10.1016/j.urolonc.2017.05.009_bib27 article-title: Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer publication-title: Urol Oncol doi: 10.1016/j.urolonc.2009.03.021 – volume: 35 start-page: 816 year: 2017 ident: 10.1016/j.urolonc.2017.05.009_bib3 article-title: Now is the time for perioperative chemotherapy in upper tract urothelial cancer |
| SSID | ssj0014811 |
| Score | 2.2132187 |
| SecondaryResourceType | review_article |
| Snippet | Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder.... Abstract Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 492 |
| SubjectTerms | Chemotherapy Female Humans Male Renal pelvis Upper tract Urologic Neoplasms Urology Urothelial cancer |
| Title | Optimizing management of upper tract urothelial carcinoma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1078143917302193 https://www.clinicalkey.es/playcontent/1-s2.0-S1078143917302193 https://dx.doi.org/10.1016/j.urolonc.2017.05.009 https://www.ncbi.nlm.nih.gov/pubmed/28579283 https://www.proquest.com/docview/1906146086 |
| Volume | 35 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-2496 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014811 issn: 1078-1439 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1873-2496 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014811 issn: 1078-1439 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2013 customDbUrl: eissn: 1873-2496 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014811 issn: 1078-1439 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection Journals customDbUrl: eissn: 1873-2496 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014811 issn: 1078-1439 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La8JAEB7EQuml9F37kBR6jSZmNyZHkYpt0R5awduSbHZB0Sg-Lj30t3fGbFJKLZYeE3bY5dtvZ2bZeQDch7jHeMtgFKnGbSYlt9EsaFtrptF6SK0DSk7u9f3ugD0N-bAE7TwXhsIqje7PdPpGW5s_dYNmfT4a1V9dqlNDiaNIUjx3VPGTqn8hp2sfRZgHevubHrw02KbRX1k89XFtvUANk1IlQzcr4Elxidvt02_-58YOdY7g0DiQVitb4zGUVHoC-z3zRH4K4QsqgenoHU2SNS1iW6yZttbzuVpYK0qLsnBJ6PlNkHyWpG5C6WwancGg8_DW7tqmP4ItWZOtbC-JQzTQjCk3ilUcxTJOPN-XKmJxgq6BI5VE98TReG2IOfe1F-ggjGQD8acaxN45lNNZqi7BSpKG5o5seq6Hm-S4OMCXXMokSELNEr8CLEdFSFM8nHpYTEQeJTYWBkxBYAqHCwSzArVCbJ5Vz9gl4OeQizw1FJWZQP2-S7C5TVAtzZFcClcsG8IRP2hTgaCQ_Ma8v0x6l7NC4Kmkp5YoVbM1ThbSTdvH-2IFLjK6FAA0At4M0au7-v_E13BAX1nY8A2UV4u1ukXnaBVXN-yvwl7r8bnb_wSgJg8T |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLbGJgEXxJvxLBLXsnZNuvaIEGhjDw6AxC1q00TaxNppjwu_HntNixBDIK5trESO_dlW_AC4CvGOMcpglKnGbSYlt9EsaFtrptF6SK0DKk7uD_z2C3t45a8VuC1qYSit0mB_julLtDZfGoabjclw2HhyqU8NFY6ikKLeeWtQYxwxuQq1m063PSgfE1iwHMNL620i-CzkaYyuF1MEmZSaGbp5D09KTVxton5yQZem6H4btowPad3kx9yBikp3Yb1vXsn3IHxEHBgP39EqWeMyvcXKtLWYTNTUmlNllIVHQufvDeXPkjRQKM3G0T683N8937ZtMyLBlqzF5raXxCHaaMaUG8UqjmIZJ57vSxWxOEHvwJFKoofiaIwcYs597QU6CCPZxCugNsTeAVTTLFVHYCVJU3NHtjzXw3tyXFzgSy5lEiShZolfB1ZwRUjTP5zGWLyJIlFsJAwzBTFTOFwgM-twXZJN8gYavxH4BctFUR2KeCYQ4n8jbK0iVDOjlTPhillTOOKb5NQhKCm_CN9fNr0spEKgYtJrS5SqbIGbhRRs-xgy1uEwF5eSAc2At0J07I7_v_EFbLSf-z3R6wy6J7BJf_Is4lOozqcLdYa-0jw-N7rwAckBEb4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimizing+management+of+upper+tract+urothelial+carcinoma&rft.jtitle=Urologic+oncology&rft.au=Campbell%2C+Matthew+T&rft.au=Shah%2C+Amishi+Y&rft.au=Matin%2C+Surena+F&rft.au=Siefker-Radtke%2C+Arlene+O&rft.date=2017-07-01&rft.issn=1873-2496&rft.eissn=1873-2496&rft.volume=35&rft.issue=7&rft.spage=492&rft_id=info:doi/10.1016%2Fj.urolonc.2017.05.009&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10781439%2FS1078143916X00191%2Fcov150h.gif |